CoChat

Combination of metformin and RG7388 enhances inhibition of growth and induction of apoptosis of ovarian cancer cells through the PI3K/AKT/mTOR pathway

Cui, Yingying, Zhou, Jing, Rong, Fengnian · 2020 · Biochemical and Biophysical Research Communications
Cited by 14

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Ovarian cancer is a gynecological cancer that has the highest mortality rate and is often resistant to conventional treatments. Therefore, development of new therapies is essential. Metformin (MET), which is the priority drug for treatment of type 2 diabetes, has received increasing attention because of its anti-tumor effects. Here, we examined combined anti-tumor effects of MET and RG7388, the only MDM2 (mouse double minute 2 homolog) antagonist that has entered phase III clinical trials, on ovarian cancer cell lines. We examined effects on proliferation by Cell Counting Kit-8 (CCK-8) and colony formation assays, and effects on apoptosis by flow cytometric analysis and Hoechst staining. Western blotting was used to measure protein expression in cells and tissues treated with MET and/or RG7388. Flow cytometry was used to measure reactive oxygen species (ROS). We also examined the effects of MET and/or RG7388 on inhibition of A2780 cell growth in vivo. The combination of MET and RG7388 significantly increased growth inhibition, apoptosis, and ROS of A2780 and SKOV3 cells compared with either agent alone. Additionally, in vitro and in vivo results showed that MET and/or RG7388 inhibited the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway and their combination had a stronger effect. Our findings suggest that the combination of MET and RG7388 enhances growth inhibition and apoptosis induction of ovarian cancer cells through the PI3K/AKT/mTOR pathway and accumulation of intracellular ROS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbrc.2020.09.135

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 8

  1. Siegel, 2020, Cancer statistics, 70, 7
  2. Lheureux, 2019, Epithelial ovarian cancer: Evolution of management in the era of precision medicine, 69, 280
  3. Li, 2018, Metformin use and its effect on gastric cancer in patients with type 2 diabetes: a systematic review of observational studies, Oncol Lett, 15, 1191
  4. Yang, 2019, Metformin improves the sensitivity of ovarian cancer cells to chemotherapeutic agents, Oncol Lett, 18, 2404
  5. Lim, 2016, Targeted therapy in ovarian cancer, Women’s Health, 12, 363
  6. Cheaib, 2015, The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges, Chin. J. Canc., 34, 4
  7. Fu, 2017, Antidiabetic drug metformin mitigates ovarian cancer SKOV3 cell growth by triggering G2/M cell cycle arrest and inhibition of m-TOR/PI3K/Akt signaling pathway, Eur. Rev. Med. Pharmacol. Sci., 21, 1169
  8. Zheng, 2018, Metformin inhibits ovarian cancer growth and migration in vitro and in vivo by enhancing cisplatin cytotoxicity, Am J Transl Res, 10, 3086

Cited by

Metadata

Authors
Cui, Y., Zhou, J., & Rong, F.
Venue
Biochemical and Biophysical Research Communications
Publisher
Elsevier BV
Published
2020-12
Volume
533
Issue
4
Pages
665-671
ISSN
0006-291X
Cited by
14
References
27
Language
en
Licence
Funders
Technology Development Project of Shandong Medical and Health Science (2017WS280)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.